TABLE 3.
Asthma Control Questionnaire (ACQ) and Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) outcome assessments
|
ICS
|
ICS/LABA
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Low-dose,n=89 | Moderate-dose,n=50 | High-dose,n=15 | P* | Low-dose, n=93 | Moderate-dose,n=51 | High-dose, n=9 | P* | |
| Asthma symptoms, n (%) | ||||||||
| Well controlled asthma at baseline | 9 (10.1) | 3 (6.0) | 0 (0.0) | 0.340 | 5 (5.4) | 1 (2.0) | 1 (11.1) | 0.403 |
| Well controlled asthma at week 8 | 57 (65.5) | 22 (44.0) | 6 (42.9) | 0.029 | 47 (52.8) | 26 (54.2) | 4 (50.0) | 0.972 |
| ACQ, mean (SD) | ||||||||
| ACQ score at baseline | 1.93 (0.79) | 2.10 (0.79) | 2.41 (0.89) | 0.084 | 2.06 (0.78) | 2.03 (0.74) | 2.00 (1.14) | 0.947 |
| ACQ score at week 8 | 0.78 (0.72) | 0.98 (0.73) | 1.09 (0.65) | 0.143 | 0.93 (0.81) | 0.97 (0.85) | 1.36 (1.58) | 0.419 |
| MiniRQLQ, mean (SD) | ||||||||
| Overall score at baseline | 2.44 (1.21) | 2.57 (1.10) | 2.58 (1.26) | 0.805 | 2.63 (1.28) | 2.79 (1.09) | 2.26 (1.54) | 0.470 |
| Overall score at week 8 | 0.96 (0.75) | 1.26 (1.10) | 0.97 (0.96) | 0.163 | 1.09 (1.02) | 1.29 (1.11) | 1.50 (1.89) | 0.429 |
| MiniRQLQ domains, mean (SD) | ||||||||
| Activities at baseline | 2.46 (1.32) | 2.59 (1.32) | 2.82 (1.08) | 0.571 | 2.66 (1.39) | 2.48 (1.28) | 2.52 (1.51) | 0.759 |
| Activities at week 8 | 0.94 (0.83) | 1.17 (1.38) | 1.07 (1.27) | 0.504 | 0.98 (0.99) | 1.05 (1.16) | 1.83 (2.11) | 0.125 |
| Practical problems at baseline | 2.70 (1.52) | 3.18 (1.49) | 3.03 (1.78) | 0.213 | 2.98 (1.57) | 3.27 (1.32) | 2.17 (1.82) | 0.113 |
| Practical problems at week 8 | 1.08 (1.06) | 1.64 (1.39) | 1.21 (1.60) | 0.041 | 1.25 (1.30) | 1.54 (1.45) | 1.69 (2.22) | 0.411 |
| Nose symptoms at baseline | 2.85 (1.28) | 2.85 (1.09) | 2.51 (1.33) | 0.590 | 2.99 (1.58) | 2.97 (1.18) | 2.33 (1.81) | 0.441 |
| Nose symptoms at week 8 | 1.03 (0.94) | 1.56 (1.37) | 1.00 (1.31) | 0.026 | 1.19 (1.22) | 1.39 (1.06) | 1.08 (1.43) | 0.600 |
| Eye symptoms at baseline | 2.04 (1.55) | 2.04 (1.38) | 2.24 (1.85) | 0.888 | 2.14 (1.59) | 2.58 (1.52) | 2.37 (2.04) | 0.296 |
| Eye symptoms at week 8 | 0.80 (0.92) | 0.89 (1.00) | 0.76 (1.11) | 0.834 | 1.03 (1.21) | 1.30 (1.39) | 1.46 (2.19) | 0.442 |
| Other symptoms at baseline | 2.25 (1.55) | 2.55 (1.70) | 2.42 (1.70) | 0.566 | 2.55 (1.55) | 2.80 (1.50) | 1.89 (1.89) | 0.250 |
| Other symptoms at week 8 | 0.98 (1.03) | 1.20 (1.24) | 0.90 (0.68) | 0.468 | 1.05 (1.23) | 1.51 (1.61) | 1.50 (2.19) | 0.181 |
*
Based on ANOVA for continuous variables and χ2 for categorical variables. An ACQ score of ≤0.75 was defined as ‘well-controlled asthma’. ICS Inhaled corticosteroid; LABA Long-acting beta-2-agonist